Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0617088/Small-Cell-Lung-Cancer-SCLC-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global SCLC therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SCLC therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData's analysis estimated the small cell lung cancer (SCLC) therapeutics market to be worth $277.8m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 3.4% over the next eight years to reach $362.3m in 2018. The growth during 2005-2010 was primarily attributed to the launch of an oral form of Hycamtin (topotecan). The steady growth rate during the forecast period is attributed to the expected launch of Amrubicin (SM-5887) in the US and Europe for the treatment of relapse/refractory SCLC patients, as well as a weak late stage pipeline with no molecules to treat newly diagnosed patients.
Scope
The report provides information on the key drivers and challenges of the SCLC therapeutics market. Its scope includes -
- Annual data on the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for SCLC therapeutics, with historic data from 2005 to 2010 and forecasts to 2018.
- Pipeline analysis data providing information on the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for SCLC fall under major therapeutic classes such as topoisomerase II inhibitors, Pan Bcl-2 inhibitors, topoisomerase I inhibitors, IGF-R1 inhibitors/hedgehog pathway inhibitors, and tyrosine kinase inhibitors.
- Analysis of the current and future competition in the global SCLC market is provided. The key market players covered are Celgene Corporation and Cephalon Inc.
- An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics coverage, including strategic a competitor assessment, market characterization and unmet needs analysis, as well as their implications for the SCLC therapeutics market.
- Analysis of key recent licensing and partnership agreements in the SCLC therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global SCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global SCLC therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global SCLC therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Small Cell Lung Cancer (SCLC) Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology 8
2.4 Risk Factors 8
2.5 Pathophysiology 9
2.6 Signs and Symptoms 9
2.7 Staging 9
2.7.1 Stages of SCLC 9
2.7.2 Anatomic Stage Classification 11
2.7.3 Tests and Procedures Used in the Staging Process 11
2.8 Survival Rates for SCLC 12
2.8.1 Limited-Stage SCLC 12
2.8.2 Extensive-Stage SCLC 12
2.9 Recurrent SCLC 12
2.10 Diagnosis 12
2.10.1 Chest X-ray 12
2.10.2 Physical Exam and History 12
2.10.3 CT Scan (CAT Scan) of the Brain, Chest, and Abdomen 12
2.10.4 PET Scan (Positron Emission Tomography Scan) 12
2.10.5 Sputum Cytology 12
2.10.6 Bronchoscopy 13
2.10.7 Fine-Needle Aspiration (FNA) Biopsy of the Lung 13
2.10.8 Thoracoscopy 13
2.10.9 Thoracentesis 13
2.11 Treatment and Management Pattern of SCLC 13
2.11.1 Surgery 13
2.11.2 Chemotherapy 13
2.11.3 Radiation Therapy 13
2.11.4 Laser Therapy 13
2.11.5 Endoscopic Stent Placement 14
2.12 Chemotherapy Regimens 14
2.12.1 Subsequent Chemotherapy 14
2.13 Treatment Options by Stage 15
2.14 GlobalData Pipeline Report Guidance 16
3 Small Cell Lung Cancer Therapeutics - Market Characterization 17
3.1 SCLC Therapeutics Market Size (2005-2010) – Global 17
3.2 SCLC Therapeutics Market Forecast (2010-2018) – Global 19
3.3 SCLC Therapeutics Market Size (2005-2010) – The US 21
3.4 SCLC Therapeutics Market Forecast (2010-2018) – The US 22
3.5 SCLC Therapeutics Market Size (2005-2010) – The UK 23
3.6 SCLC Therapeutics Market Forecast (2010-2018) – The UK 24
3.7 SCLC Therapeutics Market Size (2005-2010) – France 25
3.8 SCLC Therapeutics Market Forecast (2010-2018) – France 26
3.9 SCLC Therapeutics Market Size (2005-2010) – Germany 27
3.10 SCLC Therapeutics Market Forecast (2010-2018) – Germany 28
3.11 SCLC Therapeutics Market Size (2005-2010) – Italy 29
3.12 SCLC Therapeutics Market Forecast (2010-2018) – Italy 30
3.13 SCLC Therapeutics Market Size (2005-2010) – Spain 31
3.14 SCLC Therapeutics Market Forecast (2010-2018) – Spain 32
3.15 SCLC Therapeutics Market Size (2005-2010) – Japan 33
3.16 SCLC Therapeutics Market Forecast (2010-2018) – Japan 34
3.17 Drivers and Barriers for the SCLC Therapeutics Market 35
3.17.1 Drivers for the SCLC Therapeutics Market 35
3.17.2 Barriers for the SCLC Therapeutics Market 35
3.18 Key Events Impacting the Future Market 36
3.19 Opportunity and Unmet Need 36
3.20 Key Takeaway 38
4 SCLC Therapeutics Market - Competitive Assessment 39
4.1 Overview 39
4.1.1 Strategic Competitor Assessment 39
4.2 Profiles of the Commonly Used Products and Regimens in the SCLC Therapeutics Market 41
4.2.1 Calsed (amrubicin hydrochloride, SM-5887) 41
4.2.2 Cisplatin and Etoposide Regimen 42
4.2.3 Carboplatin and Etoposide Regimen 43
4.2.4 Cisplatin and Irinotecan Regimen 44
4.2.5 Hycamtin (topotecan) 45
4.3 Key Takeaway 45
5 SCLC Therapeutics Market - Pipeline Assessment 46
5.1 Overview 46
5.2 Strategic Pipeline Assessment 46
5.3 Small Cell Lung Cancer Pipeline Analysis – Pipeline by Clinical Phases of Development 47
5.3.1 SCLC Therapeutics – Phase III Clinical Pipeline 47
5.3.2 SCLC Therapeutics – Phase II/III Clinical Pipeline 47
5.3.3 SCLC Therapeutics – Phase II Clinical Pipeline 48
5.3.4 SCLC Therapeutics – Phase I/II Clinical Pipeline 49
5.3.5 SCLC Therapeutics – Phase I Clinical Pipeline 50
5.3.6 SCLC Therapeutics – Preclinical Pipeline 50
5.4 SCLC Pipeline by Mechanism of Action 51
5.5 SCLC Technology Trends Analytical Framework 53
5.6 SCLC Therapeutics – Promising Drugs under Clinical Development 54
5.7 Molecule Profile for Promising Drugs under Clinical Development 55
5.7.1 Alimta (pemetrexed) in Combination with Carboplatin 55
5.7.2 Camtobell (belotecan, CKD-602) plus Cisplatin 55
6 Small Cell Lung Cancer Therapeutics - Clinical Trials Mapping 57
6.1 Clinical Trials by Country (US, EU5 and Japan) 57
6.2 Clinical Trials by Phase 58
6.3 Clinical Trials by Trial Status 59
6.4 Overall Sponsors 60
6.5 Prominent Sponsors 61
6.6 Top Companies Participating in SCLC Therapeutics Clinical Trials 62
7 Small Cell Lung Cancer Therapeutics - Strategic Assessment 63
7.1 Future Market Competition Scenario 63
8 Small Cell Lung Cancer Therapeutics - Future Players in The Market 64
8.1 Introduction 64
8.2 Company Profiles 64
8.2.1 Celgene Corporation 64
8.2.2 Cephalon Inc. 68
9 Small Cell Lung Cancer Therapeutics - Licensing and Partnership Deals 71
10 Small Cell Lung Cancer Therapeutics - Appendix 73
10.1 Definitions 73
10.2 Acronyms 73
10.3 Research Methodology 74
10.3.1 Coverage 74
10.3.2 Secondary Research 74
10.3.3 Forecasting 74
10.3.4 Primary Research 77
10.3.5 Expert Panel Validation 77
10.4 Contact Us 77
10.5 Disclaimer 77
10.6 Bibliography 78
List of Tables
Table 1: Newly Diagnosed SCLC Cases in Major Markets, 2010 8
Table 2: SCLC First-line Chemotherapy Regimens 14
Table 3: SCLC Chemotherapy Regimens for Relapse/Refractory 14
Table 4: SCLC Therapeutics Market, Global, Revenue ($m), 2005–2010 17
Table 5: SCLC Therapeutics Market, Global, Forecast ($m), 2010–2018 19
Table 6: SCLC Therapeutics Market, The US, Revenue ($m), 2005–2010 21
Table 7: SCLC Therapeutics Market, The US, Revenue ($m), 2010–2018 22
Table 8: SCLC Therapeutics Market, The UK, Revenue ($m), 2005–2010 23
Table 9: SCLC Therapeutics Market, The UK, Forecast ($m), 2010–2018 24
Table 10: SCLC Therapeutics Market, France, Revenue ($m), 2005–2010 25
Table 11: SCLC Therapeutics Market, France, Forecast ($m), 2010–2018 26
Table 12: SCLC Therapeutics Market, Germany, Revenue ($m), 2005–2010 27
Table 13: SCLC Therapeutics Market, Germany, Forecast ($m), 2010–2018 28
Table 14: SCLC Therapeutics Market, Italy, Revenue ($m), 2005–2010 29
Table 15: SCLC Therapeutics Market, Italy, Forecast ($m), 2010–2018 30
Table 16: SCLC Therapeutics Market, Spain, Revenue ($m), 2005–2010 31
Table 17: SCLC Therapeutics Market, Spain, Forecast ($m), 2010–2018 32
Table 18: SCLC Therapeutics Market, Japan, Revenue ($m), 2005–2010 33
Table 19: SCLC Therapeutics Market, Japan, Forecast ($m), 2010–2018 34
Table 20: SCLC Therapeutics – Phase III Clinical Pipeline, 2011 47
Table 21: SCLC Therapeutics – Phase II/III Clinical Pipeline, 2011 47
Table 22: SCLC Therapeutics – Phase II Clinical Pipeline, 2011 48
Table 23: SCLC Therapeutics – Phase I/II Clinical Pipeline, 2011 49
Table 24: SCLC Therapeutics – Phase I Clinical Pipeline, 2011 50
Table 25: SCLC Therapeutics – Preclinical Pipeline, 2011 50
Table 26: Mechanisms of Action That Constitute the Others in the Above Pie Chart 52
Table 27: SCLC Therapeutics – Promising Drugs Under Clinical Development, 2011 54
Table 28: SCLC Therapeutics – Clinical Trials by Country, 2011 57
Table 29: SCLC Therapeutics – Clinical Trials by Phase, 2011 58
Table 30: SCLC Therapeutics – Clinical Trials by Status, 2011 59
Table 31: SCLC Therapeutics – Clinical Trials, by Overall Sponsors, 2011 60
Table 32: SCLC Therapeutics – Clinical Trials by Prominent Sponsors, 2011 61
Table 33: SCLC Therapeutics – Top Companies Participating in Clinical Trials, 2011 62
Table 34: Celgene Corporation – Oncology Pipeline, 2011 66
Table 35: Celgene Corporation – SCLC Pipeline 67
Table 36: Cephalon Inc. – Oncology Pipeline, 2011 70
Table 37: Cephalon Inc. – SCLC Pipeline 70
Table 38: SCLC Therapeutics, Global, Deals, 2011 71
List of Figures
Figure 1: SCLC – Tumor Formation in Lungs 7
Figure 2: SCLC Treatment Algorithm by Stage 10
Figure 3: SCLC Disease Progression 10
Figure 4: SCLC Anatomic Stage Classification 11
Figure 5: SCLC Treatment Options by Stage 15
Figure 6: SCLC Therapeutics Market, Global, Revenue ($m), 2005–2010 17
Figure 7: SCLC Therapeutics, Market Share ($m), 2010 18
Figure 8: SCLC Therapeutics Market, Global, Forecast ($m), 2010–2018 19
Figure 9: SCLC Therapeutics, Market Share ($m), 2018 20
Figure 10: SCLC Therapeutics Market, The US, Revenue ($m), 2005–2010 21
Figure 11: SCLC Therapeutics Market, The US, Forecast ($m), 2010–2018 22
Figure 12: SCLC Therapeutics Market, The UK, Revenue ($m), 2005–2010 23
Figure 13: SCLC Therapeutics Market, The UK, Forecast ($m), 2010–2018 24
Figure 14: SCLC Therapeutics Market, France, Revenue ($m), 2005–2010 25
Figure 15: SCLC Therapeutics Market, France, Forecast ($m), 2010–2018 26
Figure 16: SCLC Therapeutics Market, Germany, Revenue ($m), 2005–2010 27
Figure 17: SCLC Therapeutics Market, Germany, Forecast ($m), 2010–2018 28
Figure 18: SCLC Therapeutics Market, Italy, Revenue ($m), 2005–2010 29
Figure 19: SCLC Therapeutics Market, Italy, Forecast ($m), 2010–2018 30
Figure 20: SCLC Therapeutics Market, Spain, Revenue ($m), 2005–2010 31
Figure 21: SCLC Therapeutics Market, Spain, Forecast ($m), 2010–2018 32
Figure 22: SCLC Therapeutics Market, Japan, Revenue ($m), 2005–2010 33
Figure 23: SCLC Therapeutics Market, Japan, Forecast ($m), 2010–2018 34
Figure 24: SCLC Therapeutics, Key Events Impacting Future Market 36
Figure 25: Opportunity and Unmet Need in the First-line Treatment of SCLC Therapeutics Market, 2011 37
Figure 26: Opportunity and Unmet Need in the Relapsed/Refractory Treatment of SCLC Therapeutics Market, 2011 38
Figure 27: SCLC Therapeutics Market – Strategic Competitor Assessment, First-Line Treatment, 2011 40
Figure 28: SCLC Therapeutics Market – Strategic Competitor Assessment, Treatment of Relapse/ Refractory, 2011 41
Figure 29: SCLC Therapeutics Pipeline by Phase of Clinical Development, 2011 47
Figure 30: SCLC Market – Clinical Pipeline by Mechanism of Action, 2011 51
Figure 31: Technology Trends Analytical Framework of The SCLC Pipeline, 2011 53
Figure 32: SCLC Therapeutics –Technology Trends Analytical Framework of the SCLC Pipeline – Description, 2011 54
Figure 33: SCLC Therapeutics – Clinical Trials by Country, 2011 57
Figure 34: SCLC Therapeutics – Clinical Trials by Phase, 2011 58
Figure 35: SCLC Therapeutics – Clinical Trials by Status, 2011 59
Figure 36: SCLC Therapeutics – Clinical Trials by Overall Sponsors, 2011 60
Figure 37: SCLC Therapeutics – Clinical trials by Prominent Sponsors, 2011 61
Figure 38: Top Companies Participating in SCLC Therapeutics Clinical Trials, 2011 62
Figure 39: SCLC Therapeutics, Strategic Assessment, 2011 63
Figure 40: SCLC Therapeutics Market – Clinical Pipeline by Company, 2011 64
Figure 41: GlobalData Market Forecasting Model 76
Companies Mentioned
Celgene Corporation
Cephalon Inc.
To order this report:
Pathology Industry: Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article